Valuation: Zai Lab Limited

Market Cap 2.05B 16.04B 1.77B 1.65B 1.52B 2.87B 195B 2.91B 19.46B 7.65B 97.2B 7.68B 7.51B 322B P/E 2026 *
-8.15x
P/E 2027 * -9.72x
Enterprise Value 1.55B 12.17B 1.35B 1.25B 1.15B 2.18B 148B 2.21B 14.76B 5.8B 73.76B 5.83B 5.7B 244B EV / Sales 2026 *
3.47x
EV / Sales 2027 * 2.82x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 day+0.78%
1 week-10.79%
Current month-1.11%
1 month-1.11%
3 months-13.18%
6 months+8.91%
Current year+4.76%
1 week 14.07
Extreme 14.07
15.1
1 month 14.07
Extreme 14.07
16.5
Current year 12.31
Extreme 12.31
20.42
1 year 12.31
Extreme 12.31
31.4
3 years 10.56
Extreme 10.56
35.5
5 years 10.56
Extreme 10.56
119.5
10 years 10.56
Extreme 10.56
151.2
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%-10.79% - - 2.05B
+3.29%+16.98%+37.51%+2.22% 75.12B
-2.75%+48.50%+48.50%+48.50% 49.48B
+2.72%-8.27%+20.23%+179.60% 47.63B
-3.81%+6.32%-54.61%-53.87% 42.95B
-2.40%+1.16%+60.26%-23.48% 30.72B
-2.82%+2.43%+54.12%+89.44% 24.93B
-5.35%-3.86%+70.51%-53.80% 22.98B
-1.59%-4.78%-11.93%+136.89% 19.56B
-0.42%+2.66%+68.31%+128.45% 17.19B
Average -1.23%+2.60%+32.54%+50.44% 36.73B
Weighted average by Cap. -0.68%+3.33%+29.04%+42.24%

Financials

2026 *2027 *
Net sales 448M 3.51B 388M 361M 332M 627M 42.7B 638M 4.26B 1.67B 21.27B 1.68B 1.64B 70.46B 595M 4.66B 516M 480M 441M 833M 56.71B 847M 5.65B 2.22B 28.25B 2.23B 2.18B 93.59B
Net income -244M -1.91B -212M -197M -181M -342M -23.29B -348M -2.32B -912M -11.6B -917M -897M -38.43B -159M -1.25B -138M -128M -118M -223M -15.15B -226M -1.51B -594M -7.55B -597M -583M -25B
Net Debt -493M -3.87B -428M -398M -366M -692M -47.07B -703M -4.69B -1.84B -23.44B -1.85B -1.81B -77.68B -371M -2.91B -322M -300M -276M -521M -35.42B -529M -3.53B -1.39B -17.64B -1.39B -1.36B -58.46B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Date Price Change Volume
31/07/26 HKD 14.30 +0.78% 4,088,453
30/07/26 HKD 14.19 -1.46% 3,315,700
29/07/26 HKD 14.40 -3.68% 4,970,105
28/07/26 HKD 14.95 +0.54% 4,274,612
27/07/26 HKD 14.87 -3.32% 5,385,415
Trader
Investor
-
Global
-
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.28USD
Average target price
33.30USD
Spread / Average Target
+82.18%

Quarterly revenue - Rate of surprise